Skip to main content

Mineralys Therapeutics, Inc 8-K, filed Nov 4, 2026

Mineralys Therapeutics, Inc. (MLYS)

8-K 2026-11-04 For: 2026-10-29
View Original
Added on November 04, 2026

About this 8-K

Mineralys Therapeutics, Inc filed this 8-K on November 4, 2026, reporting on events of October 29, 2026.

Mineralys said lorundrostat remains on track for a December 22, 2026 PDUFA target date. Third-quarter net loss was $57.3 million, and cash, cash equivalents and investments were $624.7 million as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 5.02: Director or officer change, or executive pay
  • Item 9.01: Financial statements and exhibits